BMO Capital Markets restated their outperform rating on shares of Cooper Companies (NYSE:COO) in a report released on Friday morning. BMO Capital Markets currently has a $280.00 target price on the medical device company’s stock, up from their prior target price of $277.00.
Several other research analysts have also recently weighed in on COO. Zacks Investment Research upgraded Cooper Companies from a hold rating to a buy rating and set a $257.00 price target for the company in a research report on Tuesday, November 14th. Raymond James Financial reiterated a buy rating and set a $265.00 price target on shares of Cooper Companies in a research report on Monday, December 4th. Stifel Nicolaus reiterated a buy rating and set a $265.00 price target (down from $275.00) on shares of Cooper Companies in a research report on Friday, December 8th. Oppenheimer set a $250.00 price target on Cooper Companies and gave the company a hold rating in a research report on Friday, December 8th. Finally, Cleveland Research cut Cooper Companies from a buy rating to a hold rating in a research report on Friday, February 9th. Eight investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Cooper Companies currently has an average rating of Hold and an average target price of $267.50.
Cooper Companies (NYSE:COO) opened at $240.95 on Friday. The company has a current ratio of 2.83, a quick ratio of 1.61 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $11,810.00, a P/E ratio of 69.24, a P/E/G ratio of 1.98 and a beta of 0.61. Cooper Companies has a 12-month low of $192.24 and a 12-month high of $260.26.
In other Cooper Companies news, Director Allan E. Rubenstein sold 500 shares of the firm’s stock in a transaction that occurred on Wednesday, December 27th. The stock was sold at an average price of $222.00, for a total value of $111,000.00. Following the sale, the director now directly owns 6,590 shares of the company’s stock, valued at $1,462,980. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Stanley Md Zinberg sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $224.66, for a total value of $1,123,300.00. Following the completion of the sale, the director now directly owns 6,090 shares in the company, valued at $1,368,179.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,385 shares of company stock worth $12,289,463. 1.60% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of COO. BB&T Investment Services Inc. grew its holdings in Cooper Companies by 71.0% in the fourth quarter. BB&T Investment Services Inc. now owns 542 shares of the medical device company’s stock valued at $119,000 after purchasing an additional 225 shares during the period. Canada Pension Plan Investment Board acquired a new stake in Cooper Companies in the third quarter valued at approximately $163,000. Virtue Capital Management LLC acquired a new stake in Cooper Companies in the fourth quarter valued at approximately $195,000. FNY Managed Accounts LLC acquired a new stake in Cooper Companies in the fourth quarter valued at approximately $217,000. Finally, CAPROCK Group Inc. acquired a new stake in Cooper Companies in the fourth quarter valued at approximately $222,000. 98.55% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This article was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.themarketsdaily.com/2018/03/13/cooper-companies-coo-given-outperform-rating-at-bmo-capital-markets.html.
About Cooper Companies
The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.